This study investigates the potential hepatoprotective and renoprotective effects of phloretin in streptozotocin-induced diabetic rats. Phloretin, a natural dihydrochalcone flavonoid abundantly found in apples, exhibits antioxidant and anti-inflammatory properties. Streptozotocin-induced diabetes is associated with oxidative stress, inflammation, and organ damage, particularly in the liver and kidneys. The administration of phloretin aims to assess its ability to mitigate diabetes-induced hepatic and renal impairments. Our findings suggest that phloretin may serve as a guardian of health by conferring protection against diabetes-associated hepato and renal damage.

Phloretin, Streptozotocin, Diabetes

Patti ME, Corvera S (2010) The role of mitochondria in the pathogenesis of type 2 diabetes. Endocr Rev 31: 364-395.

Al-Amer RM, Sobeh MM, Zayed AA, Al-Domi HA (2011) Depression among adults with diabetes in Jordan: Risk factors and relationship to blood sugar control. J Diabetes Complications 25: 247-252.

Ceriello A (2003) New insights on oxidative stress and diabetic complications may lead to a “causal” antioxidant therapy. Diabetes Care 26: 1589-1596.

Giacco F, Brownlee M (2010) Oxidative stress and diabetic complications. Circ Res 107: 1058-1070.

Akpan OU, Ewa ID, Etim BE (2013) Ocimum gratissimum alleviates derangements in serum and biliary bilirubin, cholesterol and electrolytes in streptozotocin-induced diabetic rats. Int J Biochem Res Rev 3: 171-895.

Byrne CD (2012) Non-alcoholic fatty liver disease, insulin resistance and ectopic fat: a new problem in diabetes management. Diabetes Med 29: 1098- 1107.

Ikeda Y, Shimada M, Hasegawa H, Gion T, Kajiyama K, et al. (1998) Prognosis of hepatocellular carcinoma with diabetes mellitus after hepatic resection. Hepatology 27: 1567-1571.

Wang P, Kang D, Cao W, Wang Y, Liu Z (2012) Diabetes mellitus and risk of hepatocellular carcinoma: a systematic review and meta-analysis. Diabetes Metab Res Rev 28: 109-122.

Arkkila PE, Koskinen PJ, Kantola IM, Ronnemaa T, Seppanen E, et al. (2001) Diabetic complications are associated with liver enzyme activities in people with type 1 diabetes. Diabetes Res Clin Pract 52: 113-118.

Schena FP, Gesualdo L (2005) Pathogenetic mechanisms of diabetic nephropathy. J Am Soc Nephrol 16: S30-S33.

Tanios BY, Ziyadeh FN (2012) Emerging therapies for diabetic nephropathy patients: beyond blockade of the renin-angiotensin system. Nephron Extra 2: 278-282.

Forbes JM, Coughlan MT, Cooper ME (2008) Oxidative stress as a major culprit in kidney disease in diabetes. Diabetes 57: 1446-1454.